Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
First in class study of an investigational ACTH receptor antagonist aims to…
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 04, 2026 16:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
